Okogen, an ophthalmic biotechnology company, today announced the appointment of Joshua Moriarty as the new Chief Executive Officer (CEO).
San Diego, California and Melbourne, Australia--(Newsfile Corp. - March 8, 2022) - Okogen, an ophthalmic biotechnology company, today announced the appointment of Joshua Moriarty as the new Chief Executive Officer (CEO). Mr. Moriarty will immediately commence the role previously held by Co-Founder Brian Strem, PhD (CEO at Kiora Pharmaceuticals), who will remain with the company as a director.
To view the full announcement, including downloadable images, bios, and more, click here.
Key Takeaways:
- Okogen, an ophthalmic biotechnology company, today announced the appointment of Joshua Moriarty as the new Chief Executive Officer (CEO).
- With 17 years in ophthalmic product development, Joshua Moriarty will lead Okogen and the further development of OKG-0502 following positive results and clear direction forward from the interim analysis of the RUBY Trial.
- Prior to Okogen, Mr. Moriarty held various positions at Ora, Inc., a leading ophthalmic clinical research and product development firm, most recently as Executive Director.
Click image above to view full announcement.
About Adenoviral Conjunctivitis
Adenoviral conjunctivitis is a serious, highly contagious viral infection of the eye that represents more than 70% of acute conjunctivitis cases in the United States annually. (1) It is characterized by red eyes, watery discharge and is commonly associated with a sore throat. Although its diagnosis can often be achieved clinically, adenoviral conjunctivitis is often misdiagnosed as a bacterial infection which results in the overuse of antibiotics. Currently there are no FDA-approved ocular antiviral medications.
About Okogen
Okogen is a clinical-stage, ophthalmic biotechnology company focused on developing innovative therapeutics to address unmet needs in ocular diseases. OKG-0502, the company’s lead development candidate, is a treatment for the associated signs and symptoms of adenoviral conjunctivitis. Okogen is US-based company, with a wholly owned Australian subsidiary Okogen Pty. Ltd. For more information about Okogen, visit www.okogen.com and follow us on LinkedIn.
Contacts:
Joshua H. Moriarty
info@okogen.com
Source: Okogen
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/115986
